Commercialization of Products in Pharmaceutical, Biotech, and Medical Devices
Wednesday, April 6, 2022
4:00 PM-5:30 PM
CLICK HERE TO ATTEND
Commercialization of Products in Pharmaceutical, Biotech, and Medical Devices: How Science and External Affairs Drive Policy and Access
Heim Global Consulting, LLC
In the commercialization of products, medical affairs and science drive the access and policy conversation so that the right patients receive the right pharmaceuticals, therapies and treatments. Medical devices, technology and digital biomarkers have become part of the clinical development process and the entire ecosystem of how we evaluate and treat patients.
Developing a strong cross-functional team that includes Biomedical Engineering as well as a Medical Affairs function, is essential within both pharma and medical device companies. The intersection of science and technology is redefining the real-world evidence landscape is essential for Health Economics and Outcomes Research strategic decision making, oversight, evaluating evidence gaps, and interpreting the medical and clinical value of health outcomes.
Over the years, we have not only seen how medical device technology has played a critical role in the evolution of access to medicines, but also in how real-world evidence is being innovatively utilized within pharma and is impacting decision making among healthcare providers, medical affairs and External Groups, alike. Although the scope and structure of the commercialization teams may vary across industry, a strong biomedical engineering and scientific team is needed to achieve impact along patient, disease state, clinical and payer fronts.
Meg Heim has a strong leadership background in Medical Affairs, External and Public Affairs, Operations and Innovative Delivery system, as well as extensive domestic & international experience in Pharmaceutical, Medical Device and Health technology markets. A versatile leader, she has a reputation and consistent record of innovation for successful partnerships with Global and Domestic Corporate, Pharmaceutical, Biotech, Government, Advocacy and Academic groups to create consensus and build programs that create healthcare transformative change. She is a results-oriented strategic thinker who deftly bridges from strategy to implementation, utilizing her superior motivational & communication skills to build and lead top-tier global and domestic teams to achieve goals.
In 2021, Meg founded and is President of Heim Global Consulting, LLC., which provides consulting leadership in Venture Capital and Biotech space, as well as extensive domestic & international consulting support in the Pharmaceutical, Medical Device and Health technology markets. They provide strategic advisory services for Global NGO’s and Scientific Societies. Heim Global Consulting benefits from a strong group of experienced pharmaceutical executives and scientific consultants that provide senior level strategic and operational insight across all facets of the business and lifecycle.
Before founding Heim Global Consulting, Meg’s leadership at Sanofi Pharmaceuticals included Vice President, Global Head of Scientific Engagement Strategy, Operations and Program Management, in the Chief Medical Office. Previously, as Vice President, Head of NA Medical Affairs Scientific Communications, and initially as the Chief Patient Officer and Global Head of External Affairs for Cardiovascular. Prior to Sanofi, Meg was at Bristol Myers Squibb (BMS), where she held U.S. and global leadership roles in medical affairs, advocacy and policy across multiple therapeutic areas.
Meg currently sits on the Board of Directors of Healios Corporation, based in Basel Switzerland with offices in US and Spain. Healios is a Digital MedTech company that has worked with pharmaceutical companies and academic research teams in EU and US to develop and validate digital biomarkers since 2014.